General discussion and future perspectives 189 8 women: cross-sectional and longitudinal data from a Dutch screening cohort. Clin Microbiol Infect 2021; 27(1): 125.e1-.e6. 78. Dick S, Kremer WW, De Strooper LMA, Lissenberg-Witte BI, Steenbergen RDM, Meijer C, et al. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecol Oncol 2019; 154(2): 368-73. 79. Dippmann C, Schmitz M, Wunsch K, Schütze S, Beer K, Greinke C, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics 2020; 12(1): 171. 80. Kaliff M, Lillsunde Larsson G, Helenius G, Karlsson MG, Bergengren L. Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden. PLoS One 2022; 17(9): e0274825. 81. Al Roomy M, Chehadeh W, Al Awadhi R. Prediction of cervical cancer precursor lesions by quantitative methylation specific PCR: A retrospective study. Cytopathology 2023; 34(3): 204-10. 82. Dankai W, Khunamornpong S, Siriaunkgul S, Soongkhaw A, Janpanao A, Utaipat U, et al. Role of genomic DNA methylation in detection of cytologic and histologic abnormalities in high risk HPV-infected women. PLoS One 2019; 14(1): e0210289. 83. Dick S, Vink FJ, Heideman DAM, LissenbergWitte BI, Meijer C, Berkhof J. Riskstratification of HPV-positive women with low-grade cytology by FAM19A4/miR12422 methylation and HPV genotyping. Br J Cancer 2022; 126(2): 259-64. 84. Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. Int J Cancer 2021; 148(2): 396-405. 85. Chao TK, Ke FY, Liao YP, Wang HC, Yu CP, Lai HC. Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of paired boxed gene 1 (PAX1). Diagn Cytopathol 2013; 41(1): 41-6. 86. Lin H, Chen TC, Chang TC, Cheng YM, Chen CH, Chu TY, et al. Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol 2014; 135(1): 64-8. 87. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17(12): 1293-302. 88. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ 2019; 365: l1161. 89. Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K, et al. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis 2020; 222(6): 948-56. 90. Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, et al. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS Med 2021; 18(6): e1003588. 91. Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018. MMWR Morb Mortal Wkly Rep 2021; 70(12): 415-20. 92. Cuschieri K, Palmer T, Graham C, Cameron
RkJQdWJsaXNoZXIy MjY0ODMw